STRATA Skin Sciences(US:SSKN) Globenewswireยท2025-08-13 20:05Core Insights - STRATA Skin Sciences, Inc. reported its financial results for the second quarter of 2025, highlighting a strategic focus on expanding its patient population through newly approved reimbursement codes for its XTRAC Excimer laser treatment [1][3]. Financial Performance - Revenue for Q2 2025 was $7.7 million, a decrease of 9% compared to Q2 2024 [4]. - Global recurring revenue was $5.1 million, down 4% year-over-year, while equipment revenue decreased by 18% to $2.5 million [4]. - Gross profit for the quarter was $4.3 million, representing 56% of revenue, down from $5.0 million in the same quarter of the previous year [4]. - Total operating expenses increased to $6.5 million from $5.5 million in the prior-year period [5]. - The net loss for Q2 2025 was $2.5 million, or a loss per share of $0.60, compared to a net loss of $0.1 million, or a loss per share of $0.03, in Q2 2024 [5][24]. Operational Highlights - The company is managing costs while expanding its patient pool through direct-to-consumer (DTC) efforts and strengthening partnerships with practice partners [3]. - STRATA has seen a historic expansion of CPT codes for reimbursement, effectively tripling the covered patient population in the U.S. [8]. - The average gross billings per device increased by 2.7% to $5,512 compared to the prior-year period [8]. - The company removed 21 underperforming XTRAC devices and placed 19, marking the highest number of placements in six quarters [8]. Cash Position - As of June 30, 2025, cash and cash equivalents were $6.0 million, despite a payment of $1.3 million in restricted cash related to sales tax accruals [6][8].